Three other proteostasis-modifying drugs have excited interest in translating promising animal study findings into humans—GM-CSF, methylene blue and phenylbutyric acid have registered phase 2 studies on clinicaltrials.gov to test their use in Alzheimer's disease. The gene discussed is CSF2; the disease is Alzheimer disease.